Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT05001126 Completed - Metabolic Syndrome Clinical Trials

The Dose-response Effects of High Intensity Functional Training on Metabolic Syndrome Risk Factors

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study aims to explore the dose effects of three weekly volumes of high-intensity functional training (HIFT) on apolipoprotein B (ApoB), triglyceride (TG) and cholesterol (CHOL) content of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL), and high-density lipoproteins (HDL) particles, fasting insulin and glucose, glycosylated hemoglobin (HbA1c), and endothelial function after a 12-week training program. Secondarily, this study aims to also explore the subjective dose-responses of "exercise enjoyment" and "intention to continue" after this 12-week training program.

NCT ID: NCT04998201 Completed - Mixed Dyslipidemia Clinical Trials

Study of ARO-APOC3 in Adults With Mixed Dyslipidemia

MUIR
Start date: September 28, 2021
Phase: Phase 2
Study type: Interventional

Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluted for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standard of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.

NCT ID: NCT04987970 Completed - Clinical trials for Hypertension and Dyslipidemia

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

Start date: September 12, 2021
Phase: Phase 1
Study type: Interventional

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(2)

NCT ID: NCT04965948 Completed - Inflammation Clinical Trials

Effects of Camelina Sativa Oil in Free-living Older Adults

Start date: January 7, 2019
Phase: N/A
Study type: Interventional

The present study aims at evaluating the anti-inflammatory effects of a novel food in older adult volunteers. Briefly, this randomized, double-blind and placebo-controlled study is performed on 91 apparently healthy older adults (age≥65 years) before and after 12 weeks' consumption of a snack enriched with camelina Sativa oil. Subjects were randomized into two groups (active group vs placebo group).

NCT ID: NCT04951401 Completed - Clinical trials for Acute Coronary Syndrome

Pattern of Dyslipidemia Among Patients With Acute Coronary Syndrome at Sohag University Hospital

Start date: August 1, 2021
Phase:
Study type: Observational

In this study, I am aime to analyze lipid profile in patients with ACS who presents at sohag university hospital, and its clinical and complications pattern.

NCT ID: NCT04894318 Completed - Dyslipidemias Clinical Trials

The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients

Start date: September 5, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to compare LDL sub-group concentration before and after a diet with low-fat and low-cholesterol prescribed to dyslipidemic patients for 12 weeks.

NCT ID: NCT04886297 Completed - Dyslipidemias Clinical Trials

A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder

Start date: May 1, 2021
Phase: Phase 3
Study type: Interventional

In order to study the effect of resveratrol on the improvement of lipid and uric acid metabolism, randomized intervention trials were conducted to compare the effects of resveratrol on the improvement of lipid and uric acid metabolism in different dose groups. To explore the best dose of resveratrol for the prevention and treatment of metabolic diseases provide an important scientific basis.

NCT ID: NCT04885153 Completed - Diabetes Mellitus Clinical Trials

Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume

Start date: November 1, 2016
Phase: N/A
Study type: Interventional

Lipid levels in the blood are proposed to play a role in the progression of diabetic retinopathy. Lipid levels can be controlled with dyslipidemic drugs, such as fenofibrate. Fenofibrate is known to prevent diabetic microvascular complications by decreasing cholesterol and triglyceride levels. This study aims to investigate the effects of oral fenofibrate on central macular thickness (CMT) and macular volume, as well as on specific biomarkers of endothelial dysfunction (eNOS), inflammation (VCAM-1), and angiogenesis (VEGF) in DR individuals with dyslipidemia.

NCT ID: NCT04883658 Completed - Clinical trials for Hypertension and Dyslipidemia

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)

Start date: June 4, 2021
Phase: Phase 1
Study type: Interventional

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-348(2)

NCT ID: NCT04874142 Completed - Dyslipidemias Clinical Trials

Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A

Start date: November 20, 2019
Phase: Phase 1
Study type: Interventional

To evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A